Glaxo clinches £9bn bid
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Glaxo declared its £9bn bid for Wellcome unconditional yesterday, confirming the creation of the world's largest pharmaceuticals company and starting a process of integration which the two companies' employees fear could lead to the loss of 15,000 jobs.
Sir Richard Sykes, Glaxo chairman, said: "Glaxo Wellcome will combine the strengths of two great companies and will be well-positioned to meet the fundamental changes taking place in the industry."
Yesterday's announcement follows the expiry of a mandatory US regulatory waiting period, the final hurdle in the bid. Glaxo has agreed with the Federal Trade Commission to dispose of one of Wellcome's anti-migraine treatments as a condition of the deal going through.
By Wednesday, Glaxo had received acceptances on behalf of 86.1 per cent of Wellcome's shares, well ahead of the 50 per cent target it had set for declaring the bid unconditional. As a result Wellcome shareholders will not now receive a 16p dividend from the company, getting instead a 13.5p payment from Glaxo Wellcome, the combined company which officially comes into existence on 1 May.
Wellcome's migraine drug, 311C90, is one of a number under development by the company to broaden its largely anti-viral base. Glaxo already has a leading migraine drug, Imigran, which had sales of £154m in 1994, 55 percent in the US.
The merger, announced on 23 January, is Britain's biggest successful deal. It creates the world's largest pharmaceuticals group, with annual sales of £8bn and leading positions in ulcer, respiratory, cancer, antibiotic and anti-viral drugs, including Wellcome's Retrovir anti-Aids and Zovirax herpes products.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments